Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials
Allergy2021Vol. 77(4), pp. 1231–1244
Citations Over TimeTop 1% of 2021 papers
Joaquim Mullol, Tanya M. Laidlaw, Claus Bachert, Leda Mannent, Giorgio Walter Canonica, Joseph K. Han, Jorge Máspero, César Picado, Nadia Daizadeh, Benjamin Ortiz, Yongtao Li, Marcella Ruddy, Elizabeth Laws, Nikhil Amin
Abstract
In patients with uncontrolled severe CRSwNP, dupilumab significantly improved objective measures and patient-reported symptoms to a greater extent in the presence of comorbid NSAID-ERD than without. Dupilumab was well tolerated in patients with/without NSAID-ERD.
Related Papers
- → Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps(2021)45 cited
- → Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps(2021)19 cited
- → Efficacy of Dupilumab in Concomitant Atopic Dermatitis and Chronic Rhinosinusitis With Nasal Polyps: A Preliminary Study(2021)6 cited
- → P452 DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COMORBID ASTHMA: SINUS-24/SINUS-52 TRIALS(2019)
- → Faculty Opinions recommendation of Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.(2019)